AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus^[1].

Aryl hydrocarbon receptor (AhR) ^[1][2]
Prostatic VEGF^[1]
Estrogenic^[1]

AhR modulator-1 (6-MCDF; 0.1-10 μM; 48-96 hours; ASPC-1 cells) treatment exhibits dose-dependent growth inhibitory effects with growth inhibitory effects of 26, 43 and 99% at concentrations of 0.1, 1 and 10 μM, respectively^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

AhR modulator-1 (6-MCDF; 0-40 mg/kg; oral administration; daily; for 12 weeks; C57BL/6-Tg(TRAMP)8247Ng/J mice) treatment reduces the frequency of pelvic lymph node metastasis in mice fed the 40 mg/kg diet. And serum VEGF concentrations are also reduced. Prostate tumor incidence and size are not significantly reduced^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

285.55

C₁₃H₇Cl₃O

115039-00-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fritz WA, et al. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol. 2009 Apr 1;77(7):1151-60.

  [2]. Koliopanos A, et al. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene. 2002 Sep 5;21(39):6059-70.